```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, is a a valuable scientific reagent extensively used in thrombosis studies . This Fab fragment specifically targets the glycoprotein IIb/IIIa receptor on thrombocytes , preventing clot formation . Consequently , it's commonly employed as a method to explore the pathways underlying coagulation and to evaluate the effectiveness of antithrombotic therapies. Supply is typically controlled to institutional settings.
```
The Abciximab Compound Research: Utilizing C7E3 and The 143653-53-6 Substance in Studies
Ongoing studies into abciximab, a GPIIb/IIIa, frequently utilizes the monoclonal protein C7E3 and the substance identified as 143653-53-6. These tools are instrumental for analyzing abciximab's mechanism of action, assessing its effectiveness in different patient populations, and exploring potential indicators of patient outcome. Further exploration leveraging these specific reagents is likely to provide valuable insights for enhancing patient care related to cardiovascular illness.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Investigating Potential Possibilities with the Drug Abciximab 143653-53-6 via C7E3
Recent studies demonstrate that this antiplatelet agent (identified as 143653-53-6) presents significant scientific potential, particularly when associated with C7E3. Initial observations indicated that this association might boost clinical outcomes in several cardiovascular settings. Further exploration is centered on understanding the precise mode of interaction between the antiplatelet medication and C7E3, website involving assessment of blood clot cohesion and vascular safeguarding.
- Future investigation work intend to optimize administration strategies.
- Animal approaches are being utilized to more confirm such theories.
- Clinical assessments will be required to fully determine therapeutic effectiveness.
```
Abciximab (C7E3) for Research: Quality and Details (143653-53-6)
Researchers requiring abciximab for experimental research should meticulously assess quality and defined parameters . The compound is typically provided as a freeze-dried powder and detailed analytical documentation including verification by HPLC , potency assays, and endotoxin testing must be available. Verify the source’s documentation clearly states required values for related substances and meets all quality assurance guidelines.
Research-Grade ReoPro Details & Stock
Acquiring research-grade Abciximab, specifically referencing the molecule C7E3 and identified by the chemical number 143653-53-6, requires thorough consideration of its manufacturer. This antibody is frequently utilized in laboratory investigations , particularly those related to platelet aggregation and occlusion. Current vendors offer this substance in varying volumes, typically ranging from milligram to larger commercial amounts . Please recommend reviewing the documentation of testing to verify purity and suitability for your specific application . Furthermore , confirm the expiration date before obtaining to maintain ideal performance .
- Common Purity: >95%
- Preservation Conditions: -20°C and controlled conditions
- Use : Platelet Aggregation Inhibition Studies